Login to Your Account

Financings NEWS

Durham, N.C.-based Dova Pharmaceuticals Inc., a small rare disease company gearing up for the potential launch of a pre-registration drug for treating thrombocytopenia, has priced an underwritten public offering expected to raise as much as $80.9 million. Funds from the offering, in which shares will be sold at $32 each, would support a potential June launch of avatrombopag in the U.S. for patients with chronic liver disease, and work to expand the drug's approved uses to the treatment of a broader population of patients with thrombocytopenia.

Kallyope Inc., a growing biotech focused on modulating the gut-brain axis to treat metabolic and neurological disorders, has raised $66 million that will help carry its first compounds toward the clinic and ongoing development of its discovery platform, CEO Nancy Thornberry told BioWorld.

ORIC Pharmaceuticals Inc., a South San Francisco-based company going after treatment-resistant solid tumors with an oral glucocorticoid receptor inhibitor, ORIC-101, has completed a $50 million series C financing.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: